Endosense has announced that its TactiCath Quartz force-sensing ablation catheter has been CE mark approved. In cooperation with the company’s distributor Biotronik, first cases using the new device have been performed by renowned physicians at three centres across Europe.
Cardiac Ablation
CardioFocus HeartLight Ablation Study Demonstrates Durable Pulmonary Vein Isolation In Treatment Of Atrial Fibrillation
CardioFocus, Inc.is drawing our attention to a study in the journal Heart Rhythm, demonstrating 98% acute success and durable pulmonary vein (PV) isolation rates achievable with a single, visually-guided HeartLight EAS ablation procedure.
U.S. Launch of Boston Scientific’s Z Flex-270™ Steerable Ablation Catheter Sheath
Boston Scientific has announced the immediate launch of its new Z Flex-270 steerable sheath to enable Cardiologists to precisely steer ablation catheters of up to 12F to target tissue.
FDA Approves AtriCure’s Synergy Ablation System For Atrial Fibrillation Treatment
First and Only System in the United States Approved to Treat Patients with Persistent and Long-Standing Persistent Atrial Fibrillation
Growth And Uptake Of Ablation Technologies: Report
Medmarket Diligence has released a report detailing the Global trends in use of ablation technology between 2009 and 2019 showing how significant this market has become and how different ablative technologies are predicted to show differing rates of uptake.
AtriCure Stops Recruiting For DEEP AF Feasibility Trial
AtriCure, Inc. a leader in cardiac surgical ablation systems has announced that it has closed enrollment in its DEEP AF feasibility trial, believing a staged approach will be more favourable for investigators in its forthcoming pivotal trial.
American Heart Association Scientific Sessions: Catheter Ablation Outperforms Drugs For Periodic Atrial Fibrillation
American Heart Association Clinical Trial Report indicates that Radiofrequency ablation of target heart tissue shows better results than drug therapy in reducing atrial fibrillation.
FDA Advisory Panel Makes Recommendation on Investigational Medtronic Phased RF Ablation System for Treatment of Persistent or Long-Standing Persistent Atrial Fibrillation
Medtronic has announced that the FDA Circulatory Systems Devices advisory panel has voted against the company’s Phased RF Ablation System,
Atricure’s Press Release confirms FDA Panel decision re: Synergy Ablation Indication
Circulatory System Devices Panel Votes in Favor of FDA Approval for AtriCure’s Surgical Ablation System to Treat Atrial Fibrillation
AtriCure Wins Panel Backing for Atrial Fibrillation Indication
An advisory panel to the FDA has voted 5-3, with one abstention, to recommend Atricure’s ablation device for patients with atrial fibrillation.
Atricure’s PMA approval for Atrial Fibrillation indication under scrutiny this week
Cardiac device maker Atricure (NASDAQ:ATRC) share price dropped on Monday after an FDA report expressed “concerns” about a clinical trial intended to support expansion of indications for one of the company’s ablation devices.